Home » Topics » BioWorld Science

BioWorld Science
RSS

Enteris reports results from final arm of phase IIa trial of Ovarest

June 27, 2018

Increasing the sensitivity of mu-opioid receptors

June 27, 2018

Stemline Therapeutics completes rolling BLA submission to the FDA for Elzonris

June 27, 2018

Phase II results for CLT-008 in patients receiving AML induction therapy

June 27, 2018

First-in-human data reported for AMV-564 in patients with relapsed/refractory AML

June 27, 2018

Safety and immunogenicity of ZMapp antibody cocktail for Ebola virus tested in healthy adults

June 27, 2018

Navitor Pharmaceuticals initiates phase I trial of NV-5138 for treatment-resistant depression

June 27, 2018

AD and ID

June 27, 2018

CHMP adopts positive trend vote recommending the approval of the MAA for neratinib

June 27, 2018

Prespecified efficacy endpoint met in phase II study of bemcentinib plus Keytruda in NSCLC

June 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...